Advances in the Diagnosis and Treatment of Lung Adenocarcinoma–Part II

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (24 April 2024) | Viewed by 183

Special Issue Editors

E-Mail Website
Guest Editor
Department of Thoracic Surgery, Hammersmith Hospital, London, UK
Interests: lung cancer; minimally invasive thoracic surgery; translational medicine; health policy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Imperial College Healthcare NHS Trust, London, UK
2. 424 General Military Hospital, Thessaloniki, Greece
Interests: cardiothoracic surgery; thoracic surgical oncology; lung cancer; tracheal disease; coronary artery disease; cardiac valve disease; thoracic trauma; military medicine; translational cardiovascular medicine; surgical education and simulation; health policy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide, with an estimated 2.2 million new cases and 1.8 million deaths in 2020. The histological pattern of lung cancer changed significantly over a period of only a few decades, with a decrease in squamous cell carcinoma and a sharp rise in adenocarcinoma. Currently, adenocarcinoma represents the most common histologic type of pulmonary tumors, accounting for more than 65% of all lung cancers. Of interest, it is also the most common form of lung cancer in people who have never been smokers. With the recent introduction of lung cancer screening programs and the increasing detection of adenocarcinoma spectrum lesions (e.g., adenocarcinoma in situ, minimally invasive adenocarcinoma), the number of newly diagnosed cases is expected to further rise.

Apart from changes in the epidemiology and biology of lung cancer, significant advances have recently occurred in the diagnosis and treatment of the disease. The discovery of treatable oncogenic alterations has led to the routine implementation of molecular testing in the diagnostic evaluation of patients with lung adenocarcinoma. Indeed, an increasing number of targetable gene alterations has been recently identified, enabling individualized therapies that have demonstrated remarkable responses in selected patients. Targeted therapies were initially used for the management of advanced lung adenocarcinoma, but they have also recently shown promising results in early disease as part of multimodality treatments. This success of targeted therapies has resulted in ongoing efforts to identify and therapeutically target other driver mutations. Furthermore, important progress has been achieved in the development of immunotherapies, which now constitute the first line treatment of advanced, wild-type lung adenocarcinomas. Moreover, a paradigm shift in the surgical management of small, peripheral adenocarcinomas, which may radiologically manifest as subsolid lung nodules, has been recently observed. Sublobar resections in the form of segmentectomy or even wedge resection have been increasingly adopted by thoracic surgeons as a valid alternative to the traditional lobectomy. Such lesions may be also successfully treated with stereotactic ablative radiotherapy, which is being currently investigated as an alternative to surgical resection.

It becomes evident that the landscape of lung adenocarcinoma is transforming rapidly. This has created great opportunities for research in diagnosis and treatment; however, it has also presented challenges to clinicians, who are often presented with an excessive amount of new information. This Special Issue, entitled “Advances in the Diagnosis and Treatment of Lung Adenocarcinoma”, aims to provide the readers of the Journal of Clinical Medicine with concise, high-quality, and up-to-date knowledge, as well as to present evidence thus far unpublished on this topic. Therefore, it welcomes both reviews and original articles. By discussing the advances in the diagnosis and treatment of lung adenocarcinoma and identifying avenues for future research, this Special Issue will be a valuable resource for researchers, clinicians, and patients alike.

Dr. Marco Scarci
Dr. Savvas Lampridis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • biomarkers
  • chemotherapy
  • immunotherapy
  • lung adenocarcinoma
  • lung surgery
  • molecular targeted therapy
  • non-small cell lung cancer
  • radiotherapy
  • screening

Related Special Issue

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop